News
New Avicenna APAC Task Force
The new APAC Task Force joined the International Affairs Working Group!
Cécile De Coster is the new Avicenna Pharmaceutical Strategy Task Force Co-chair
We are proud to welcome Cécile De Coster as the new Avicenna Pharmaceutical Strategy Task Force co-chair!
Avicenna Alliance goes on growing by welcoming Edwards Lifesciences as a new member!
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.
The Avicenna Alliance is proud to announce the newest addition to its list of members: SmartCatch!
SmartCatch is a deeptech start-up with disruptive technological know-how. Located at the heart of the Toulouse Oncopole, the start-up intends to provide oncology research and treatment centres with a series of cutting-edge microtechnology-based devices that can be used in clinical routine to isolate blood-based biomarkers for longitudinal monitoring of cancerous pathology and customization of the therapeutic strategy.
Avicenna Alliance is honoured to welcome Alfasigma as a new member!
Privately owned, Alfasigma is one of the leading Italian pharmaceutical companies, present in over 90 countries, through distributors and subsidiaries and has a workforce of around 3,000 people, R&D laboratories, and 5 production plants.
EU-funded project successfully develops AI software that grows and treats cancerous tumors
The Horizon Europe 2020 project EVO-NANO (Evolvable platform for programmable nanoparticle-based cancer therapies) has published the results of their recent research. The researchers, coming from seven different institutions, developed a platform that grows and treats virtual tumors using artificial intelligence (AI).
